.Charles Baum, M.D., Ph.D., who oversaw Mirati Rehabs' $ 5.8 billion sale to Bristol Myers Squibb in 2014, is taking the reins of young biotech Terremoto Biosciences.Baum's "comprehensive experience in drug advancement, as well as effective track record beforehand high-impact medicines, will certainly be instrumental," outbound CEO Peter Thompson, M.D., said in a July 25 release. Thompson will keep his chair as board chairperson..Baum, a qualified physician-scientist, was the owner, president as well as chief executive officer of oncology-focused Mirati. Prior to that, he aided create cancer drugs at Pfizer and also Schering-Plough..
Charles Baum, M.D., Ph.D.(( Mirati)).Currently, Baum is going to work as chief executive officer at Terremoto, a company building little particles to target disease-causing proteins-- like those found in cancerous lump cells-- using covalent bonds. Existing therapies that make use of covalent connections primarily target the amino acid cysteine. Nonetheless, of the twenty amino acids that comprise healthy proteins, cysteine is actually the least typical. Terremoto is instead targeting some of the vital amino acids, amino acid lysine, which is located in almost all proteins.By targeting amino acid lysine and various other amino acids, Terremoto plans to manage earlier undruggable health conditions and also make first-in-class medications..The biotech, based in South San Francisco, raised $75 million in series A financing in 2022. A little bit of much more than a year later on, the biotech more than increased that amount in a $175 thousand set B.